Not investment advice. FilingSight is an automated analytical research tool, not a registered investment advisor. Ratings and scores are quantitative analytical classifications, not buy or sell recommendations. Nothing here is personalized to your circumstances. Investing involves risk of loss — consult a licensed professional. See full disclosures.
Create a free account to read 3 full reports each month — plus a 14-day Pro trial. Get started →
Coca-Cola Co.
KOConsumer StaplesGenerated Jul 5, 2026, 08:09 PM UTC
KO (Coca-Cola Co.) analytical snapshot. Revenue grew +6.4% YoY to $45.75B. Net margin at 23.42% (contracting ▼). Return on equity 43.10%, ROA 10.66%, ROIC 45.51%. Market cap $362.01B at $84.14 per share. Trailing P/E 34.06, P/S 7.91, P/B 10.76. EV/Operating income ≈ 34.30 (EV $387.93B). Risk: Moderate. Macro: Risk-on · Supportive. Composite analytical score 1 (data confidence 82%). Descriptive analytics from public filings — not investment advice.
Market cap
$362.01B
4.30B shares
Price
$84.14
NYQ
P/E (ttm)
34.06
Revenue (FY)
$45.75B
YoY +6.4%
Net margin
23.42%
▼ 0.05pp
Free cash flow
$9.75B
21.30% margin
Risk level
Moderate
Free SEC analysis
— computed from SEC filings, free to readFree previewFundamentals Analyst
Fundamentals
Fundamentals Analyst
score 50Improving
80% conf
Revenue grew +6.4% YoY to $45.75B. Net margin at 23.42% (contracting ▼). Return on equity 43.10%, ROA 10.66%, ROIC 45.51%.
- Revenue grew +6.4% YoY to $45.75B.
- Net margin at 23.42% (contracting ▼).
- Return on equity 43.10%, ROA 10.66%, ROIC 45.51%.
- Gross margin 59.52%, operating margin 24.72%.
- Free cash flow margin 21.30% ($9.75B).
- Net income up ▲ +12.3% YoY.
- Debt/equity 1.09, current ratio 1.36, net debt $25.92B.
- Asset turnover 0.44 — capital efficiency.
Revenue (FY)
$45.75B
YoY +6.4%
Net margin
23.42%
▼ 0.05pp
ROE
43.10%
ROA 10.66%
ROIC
45.51%
EPS (diluted)
$2.47
FY2025
Free cash flow
$9.75B
21.30% margin
Debt / equity
1.09
Cash $10.57B
Current ratio
1.36
Equity $33.63B
Annual fundamentals — up to 10 years (SEC 10-K, US-GAAP)
| FY | Revenue | Rev YoY | Gross% | Op% | Net% | FCF | ROE% |
|---|---|---|---|---|---|---|---|
| 2016 | — | — | — | — | — | $8.21B | 27.78 |
| 2017 | — | — | — | — | — | $7.97B | 31.87 |
| 2018 | $41.86B | — | 60.67 | 20.68 | 15.59 | $6.53B | 38.23 |
| 2019 | $36.21B | -13.5% | 62.11 | 21.42 | 3.45 | $5.29B | 7.35 |
| 2020 | $34.30B | -5.3% | 61.90 | 26.68 | 18.76 | $6.08B | 33.90 |
| 2021 | $37.27B | +8.6% | 60.77 | 27.06 | 23.94 | $8.42B | 46.22 |
| 2022 | $33.01B | -11.4% | 59.31 | 27.25 | 23.47 | $8.67B | 33.68 |
| 2023 | $38.66B | +17.1% | 60.27 | 26.67 | 25.28 | $11.26B | 40.54 |
| 2024 | $43.00B | +11.3% | 58.14 | 25.37 | 22.19 | $9.53B | 36.78 |
| 2025 | $45.75B | +6.4% | 59.52 | 24.72 | 23.42 | $9.75B | 43.10 |
Quarterly revenue trend (last 6 quarters, SEC 10-Q)
| Quarter end | Revenue | YoY | QoQ | Net margin |
|---|---|---|---|---|
| Mar 28, 2025 | $11.13B | — | — | 29.92% |
| Jun 27, 2025 | $23.66B | — | +112.6% | 30.17% |
| Jun 27, 2025 | $12.54B | — | -47.0% | 56.96% |
| Sep 26, 2025 | $36.12B | — | +188.1% | 30.00% |
| Sep 26, 2025 | $12.46B | — | -65.5% | 87.00% |
| Apr 3, 2026 | $12.47B | — | +0.1% | 31.46% |
Revenue (annual, SEC 10-K)
2016: 0
2017: 0
2018: 41,863
2019: 36,212
2020: 34,300
2021: 37,266
2022: 33,014
2023: 38,655
2024: 43,004
2025: 45,754
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Profitability trends (%)
GrossOperatingNet
Free cash flow (annual)
2016: 8,209
2017: 7,975
2018: 6,530
2019: 5,291
2020: 6,079
2021: 8,417
2022: 8,667
2023: 11,258
2024: 9,534
2025: 9,747
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Sources:SEC EDGAR — Company Facts (XBRL)
Free previewRegulatory Analyst
Filings & Ownership
Regulatory Analyst
score 0Stable
80% conf
Latest annual report (10-K) filed Feb 20, 2026. Latest quarterly report (10-Q) filed Apr 30, 2026. 8 recent 8-K material-event filings in the index.
- Latest annual report (10-K) filed Feb 20, 2026.
- Latest quarterly report (10-Q) filed Apr 30, 2026.
- 8 recent 8-K material-event filings in the index.
- Recent insider Form 4s: 0 buy vs 11 sell transactions — net selling $64.1M.
- ~10,000+ recent 13F-HR filings reference Coca-Cola Co.; broad institutional reporting.
- Recent filers include BERKSHIRE HATHAWAY INC (BRK-A, BRK-B), BERKSHIRE HATHAWAY INC (BRK-A, BRK-B), BERKSHIRE HATHAWAY INC (BRK-A, BRK-B).
- 1 recent 13D activist/beneficial-ownership filings — potential catalyst.
- 19 recent 13G passive institutional ownership notices.
Latest 10-K
Feb 20, 2026
Annual report
Latest 10-Q
Apr 30, 2026
8-K (recent)
8
Insider net
-$64.1M
0B/11S
13F filers
10k+
Activist 13D
1
Recent 13F institutional filers (SEC EDGAR full-text)
| Filer | Form | Filed |
|---|---|---|
| BERKSHIRE HATHAWAY INC (BRK-A, BRK-B) | 13F-HR | May 15, 2025 |
| BERKSHIRE HATHAWAY INC (BRK-A, BRK-B) | 13F-HR | May 15, 2026 |
| BERKSHIRE HATHAWAY INC (BRK-A, BRK-B) | 13F-HR | Feb 17, 2026 |
| BERKSHIRE HATHAWAY INC (BRK-A, BRK-B) | 13F-HR | Feb 14, 2022 |
| BERKSHIRE HATHAWAY INC (BRK-A, BRK-B) | 13F-HR | Nov 14, 2024 |
Recent insider Form 4 activity
| Insider | Date | Net | Buys/Sells |
|---|---|---|---|
| MANN JENNIFER K | Jun 12, 2026 | -$2.0M | 0/1 |
| MANN JENNIFER K | Jun 11, 2026 | -$8.1M | 0/3 |
| MANN JENNIFER K | Jun 10, 2026 | -$7.9M | 0/2 |
| MANN JENNIFER K | Jun 9, 2026 | -$7.9M | 0/2 |
| Quincey James | Jun 8, 2026 | -$35.6M | 0/2 |
| QUAN NANCY | May 19, 2026 | -$2.6M | 0/1 |
Recent 8-K material events
| Date | Form | Description |
|---|---|---|
| Jun 25, 2026 | 8-K | Material current event |
| May 1, 2026 | 8-K | 8-K |
| Apr 28, 2026 | 8-K | 8-K |
| Feb 20, 2026 | 8-K | 8-K |
| Feb 10, 2026 | 8-K | 8-K |
| Jan 14, 2026 | 8-K | Material current event |
| Dec 10, 2025 | 8-K | Material current event |
| Oct 21, 2025 | 8-K | 8-K |
Insider Form 4 sentiment (transactions)
Buys: 0
Sells: 11
Buys
Sells
Free previewSEC Filing Analyst
SEC Filing Deep-Analysis
SEC Filing Analyst
score -49Deteriorating
68% conf
3 risk signal(s), 1 watch item(s) detected from XBRL filing diff analysis. 3 risk signal(s) detected versus 0 positive signal(s). The balance of evidence suggests elevated filing-specific risk that warrants monitoring in subsequent filings.
- NEW: Going concern doubt in latest filing: The term "going concern" appears in recent 10-K/10-Q filings but was NOT present in the prior 24-month period. This is a new risk disclosure that warrants attention. Found in 2 filing(s).
- Material weakness in internal controls: The term "material weakness" appears in 19 recent filing(s) (vs 2 in the prior period). This risk language is ongoing.
- NEW: Restatement of financial statements in latest filing: The term "restate" "financial statements" appears in recent 10-K/10-Q filings but was NOT present in the prior 24-month period. This is a new risk disclosure that warrants attention. Found in 3 filing(s).
- NEW: Off-balance sheet arrangements: Off-balance sheet arrangements appears in recent filings but not in the prior 24-month period. Monitor for materiality.
- Endogenous analysis: 3 risk signal(s) detected versus 0 positive signal(s). The balance of evidence suggests elevated filing-specific risk that warrants monitoring in subsequent filings.
- 20 disclosure(s) dropped from prior year — reduced reporting granularity.
- 3 new risk-language term(s) detected in filing text: Going concern doubt, Restatement of financial statements, Off-balance sheet arrangements.
- Ongoing high-severity risk language: Material weakness in internal controls.
Revenue
$45.75B
+6.4% YoY
Gross profit
$27.23B
+8.9% YoY
Operating income
$11.31B
+3.7% YoY
Net income
$10.71B
+12.3% YoY
Operating cash flow
$11.60B
+5.3% YoY
Capex
$1.85B
+24.8% YoY
Total assets
$100.55B
+2.9% YoY
Long-term debt
$36.78B
-6.8% YoY
Filing quality score
65/100
stable
SEC XBRL metric changes (latest annual vs prior)
| Metric | Prior year | Latest year | Change | % Change |
|---|---|---|---|---|
| Revenue | $43.00B | $45.75B | $2.75B | +6.4% |
| Gross profit | $25.00B | $27.23B | $2.23B | +8.9% |
| Operating income | $10.91B | $11.31B | $402.0M | +3.7% |
| Net income | $9.54B | $10.71B | $1.17B | +12.3% |
| Operating cash flow | $11.02B | $11.60B | $581.0M | +5.3% |
| Capex | $1.48B | $1.85B | $368.0M | +24.8% |
| Total assets | $97.70B | $100.55B | $2.85B | +2.9% |
| Long-term debt | $39.45B | $36.78B | $-2.68B | -6.8% |
| Cash & equivalents | $9.52B | $9.37B | $-153.0M | -1.6% |
| Stockholders equity | $25.94B | $24.86B | $-1.08B | -4.2% |
| Inventory | $4.42B | $4.73B | $304.0M | +6.9% |
| Accounts receivable | $3.41B | $3.57B | $159.0M | +4.7% |
| SG&A expense | $12.88B | $13.97B | $1.09B | +8.5% |
| Interest expense | $882.0M | $1.53B | $645.0M | +73.1% |
XBRL disclosure changes (new vs dropped concepts)
| Type | Concepts |
|---|---|
| Removed | AccountsPayableTradeCurrent, AccountsReceivableSale, AccruedMarketingCostsCurrent, AdvertisingExpense, AllocatedShareBasedCompensationExpense, AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount, AssetImpairmentCharges, BusinessCombinationContingentConsiderationLiability, BusinessExitCosts1, CurrentFederalTaxExpenseBenefit |
Risk language in filing text (EDGAR full-text search)
| Term | Severity | Recent | Prior | Status |
|---|---|---|---|---|
| Going concern doubt | high | 2 | 0 | NEW |
| Material weakness in internal controls | high | 19 | 2 | Ongoing |
| Restatement of financial statements | high | 3 | 0 | NEW |
| Impairment charge | medium | 102 | 8 | Ongoing |
| Restructuring | medium | 114 | 8 | Ongoing |
| Off-balance sheet arrangements | medium | 21 | 0 | NEW |
| Related party transactions | low | 9 | 0 | NEW |
Filing signal breakdown
Red flags: 3
Positive: 0
Watch: 1
Red flags
Positive
Watch
Unlock the rest
- ProValuationMarket cap $362.01B at $84.14 per share.
- ProPrice & TechnicalsPrice $84.14 — uptrend (above 200-DMA); 1-month momentum positive.
- ProMacro & RatesMarket regime: Risk-on · Supportive.
- ProRisk ScorecardComposite risk: Moderate.
This content is for Pro subscribers
Unlock the full breakdown from all analysts — valuation (DCF & Graham), price & technicals, macro, risk scorecard, and 13F/13D ownership flow — plus your research workspace.
3 sections free · 4 Pro sections locked · composite 1
Macro exposure
Defensive · Low sensitivityMacro regime: Risk-on · Supportive. Coca-Cola Co. is a defensive name (low macro sensitivity) — a supportive backdrop, though defensives lag risk-on tapes.
Macro regime
Risk-on · Supportive
Yield curve
Normal
VIX
16.59
Fed funds
3.63%
CPI YoY
+4.2%
Analytical read
deterministic previewRevenue grew **+6.4%** YoY to $45.75B..
Risk
Moderate
Macro regime
Risk-on · Supportive
Macro exposure
Neutral
Descriptive analytics from public filings and macro data — not investment advice.
Peer comparison
Defensive groupHow KO stacks up against tracked peers with similar macro sensitivity — by analytical score and macro exposure.
| Company | Score | Macro |
|---|---|---|
| Bristol-Myers Squibb BMY | 12 | Neutral |
| Cigna Group CI | 9 | Neutral |
| Procter & Gamble PG | 9 | Neutral |
| UnitedHealth Group UNH | 6 | Neutral |
| CVS Health Corp. CVS | 6 | Neutral |
| Zoetis Inc. ZTS | 3 | Neutral |
| Eli Lilly & Co. LLY | 3 | Neutral |
| Colgate-Palmolive CL | 1 | Neutral |
| Coca-Cola Co. KO● you | 1 | Neutral |
| Gilead Sciences GILD | 1 | Neutral |
| Intuitive Surgical Inc. ISRG | -1 | Neutral |
| Moderna Inc. MRNA | -4 | Neutral |
| Regeneron Pharmaceuticals REGN | -4 | Neutral |
| DexCom Inc. DXCM | -7 | Neutral |
| AbbVie Inc. ABBV | -7 | Neutral |
| Johnson & Johnson JNJ | -7 | Neutral |
| Vertex Pharmaceuticals VRTX | -8 | Neutral |
| Kimberly-Clark Corp. KMB | -10 | Neutral |
| Sysco Corp. SYY | -10 | Neutral |
| Danaher Corp. DHR | -11 | Neutral |
| Mondelez International MDLZ | -11 | Neutral |
| Merck & Co. MRK | -11 | Neutral |
| Biogen Inc. BIIB | -11 | Neutral |
| Amgen Inc. AMGN | -14 | Neutral |
| HCA Healthcare HCA | -14 | Neutral |
| Illumina Inc. ILMN | -16 | Neutral |
| Kroger Co. KR | -16 | Neutral |
| Thermo Fisher Scientific TMO | -18 | Neutral |
| Costco Wholesale COST | -18 | Neutral |
| PepsiCo Inc. PEP | -21 | Neutral |
| Walmart Inc. WMT | -25 | Neutral |
| Hershey Co. HSY | -26 | Neutral |
| Abbott Laboratories ABT | -30 | Neutral |
| Pfizer Inc. PFE | -49 | Neutral |